FDA Approves BKEMV — Amgen Inc
On Wednesday, Amgen Inc announced that the U.S. FDA approved BKEMV (eculizumab-aeeb) injection, expanding its portfolio of rapid-acting, interchangeable products for the complement-mediated disorders market. Commercialization is set to begin this quarter, offering a flexible alternative to traditional treatments and positioning Amgen to defend its market share against biosimilar competition.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed